Wysdom Radio™

Wysdom

5.0 (2)
Medicine

We deliver short, focused episodes on the main concepts and procedures you actually need to know. It’s the perfect clinical companion for your drive to work or your daily workout. Come learn IR on the go! Check us out at https://www.medicalwysdom.ai/

5d ago

Communicating After Complications: The Untaught Procedure

This episode features a recorded lecture by Dr. Gary Ansel on the "last untaught procedure": communicating with patients and families after a procedural complication, introduced by Dr. Rusty Hofmann. It's the kind of firsthand teaching we're proud to bring to Wysdom. The Premise: Every proceduralist remembers their first catastrophic complication. We rehearse wire crossings and balloon inflations, but almost none of us were taught what to say when we walk into the waiting room afterward.Why It Matters: The US sees 70,000 to 90,000 malpractice claims a year, 25,000 to 40,000 of them related to procedures. Most complications don't become lawsuits because of the complication itself. Many begin because patients believe information was withheld.Complication vs. Error: A complication is a known procedural risk that can occur despite excellent care. A medical error is a preventable deviation from acceptable care, and it should be acknowledged honestly. Either way, don't blame the nurses, the industry rep, the equipment or another physician, and don't declare fault or malpractice, because negligence is a legal conclusion that requires a structured review.The Conversation: Explain what happened, the patient's current condition, what is known and unknown, the immediate plan, and when the family will hear from you again. Lead with empathy, and avoid speculation, blame, defensiveness and jargon.A Case: In a PCI perforation that led to tamponade and a trip to the OR, Dr. Ansel led the family conversation himself, then held a same-day team debrief and reviewed the case for system and training improvements.The Curriculum Gap: Communication-and-resolution programs outperform deny-and-defend, with greater family trust, fewer lawsuits and lower liability costs. Yet post-complication disclosure is rarely standardized or assessed in residency, largely absent from fellowship training, and missing from the major meetings. Dr. Ansel's CLEAR framework offers a structured approach.Tune in to learn why the procedure ends when the sheath comes out, but professionalism begins when you walk into the family waiting room.
Oct 28

Early TIPS in Acute Variceal Bleeding

This Fundamentals episode breaks down the landmark Early TIPS trial (Garcia-Pagán et al., NEJM 2010) on preemptive covered TIPS for high-risk acute esophageal variceal bleeding. Following, there is an expert commentary by Dr. Michael D. Darcy, retired chief of interventional radiology at Mallinckrodt Institute of Radiology, Washington University in St. Louis. The Premise: Standard care (vasoactive drugs, antibiotics, and banding) fails in 10–15% of patients. Rescue TIPS controls bleeding but often arrives too late, when mortality is already high.The Study: Nine European centers randomized 63 high-risk patients (Child-Pugh C 10–13, or Child-Pugh B 7–9 with active bleeding at endoscopy) within 24 hours of admission to early PTFE-covered TIPS (within 72 hours) versus drugs plus banding with rescue TIPS allowed.Efficacy: The primary composite (failure to control bleeding or clinically significant rebleeding at one year) hit 1 of 32 early-TIPS patients versus 14 of 31 on standard care (P=0.001). One-year freedom from that endpoint was 97% versus 50% (NNT 2.1).Survival: Deaths were 4 versus 12. Six-week survival was 97% versus 67% (NNT 3.3); one-year survival was 86% versus 61% (NNT 4.0).Safety & burden: No technical failures. Hepatic encephalopathy at one year was 28% versus 40% (not statistically significant). ICU days were 3.6 versus 8.6.Caveats: Small open-label trial (63 of 359 screened), highly selected population, one-sided sample-size calculation, baseline imbalance in prior encephalopathy, and educational grant support from Gore.Expert Take: Dr. Darcy puts the paper in context for endovascular practice — why hepatology-led dissemination mattered, why encephalopathy still deserves respect, and why current Viatorr controlled-expansion technique often starts at 6 mm rather than the trial’s 8→10 mm step-up.Tune in to learn when early covered TIPS belongs in the pathway for high-risk variceal bleed. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Garcia-Pagán JC, C**a K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362(25):2370-2379.
Oct 21

Ablate (RFA) and Stabilize (Cement): OsteoCool RFA for Painful Bone Metastases, with Dr. Jason Levy (OPuS One)

This masterclass episode breaks down OPuS One, the prospective, multinational study of OsteoCool radiofrequency ablation (RFA) plus cement for painful lytic metastases of the spine and pelvis. Following, there is an expert commentary by Dr. Jason R. Levy of Northside Hospital, Atlanta. The Premise: External beam radiation can take 3 to 6 weeks to relieve bone metastasis pain. OPuS One asked whether ablating the tumor and stabilizing the bone could bring relief faster and keep it.The Study: 206 patients were treated at 15 centers, with lytic or mixed lesions in the thoracolumbar spine, periacetabulum, iliac crest or sacrum. Cement followed RFA in 97% of cases, and technical success was 99%.Efficacy: Worst pain, average pain, pain interference and quality of life improved significantly by day 3, and the improvement was sustained through 12 months.Durability: Complete or partial pain response rose from 53% at day 3 to 74% at 12 months (of n=59), and more patients lowered their opioid dose than raised it at every visit.Safety: Device- or procedure-related adverse events occurred in 6 of 206 patients (2.9%), with no fractures at treated sites.Caveats: OPuS One was a single-arm, industry-funded (Medtronic) study with no comparator and heavy dropout, and the effect of RFA can't be separated from the cement.Expert Take: Dr. Levy explains where ablation and cement fit alongside radiation and systemic therapy in palliative oncology, and what endovascular and image-guided specialists can offer patients with painful bone metastases.Tune in to learn how a single minimally invasive procedure can bring pain relief from bone metastases in days rather than weeks. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Levy J, David E, Hopkins T, et al. Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study. Cardiovasc Intervent Radiol. 2023;46(5):600-609. https://doi.org/10.1007/s00270-023-03417-x
Oct 14

EMMY at 10 Years: Two-Thirds Avoid Hysterectomy

This fundamentals episode breaks down the 10-year results of the EMMY trial, the Dutch randomized comparison of uterine artery embolization (UAE) versus hysterectomy for symptomatic uterine fibroids, and the longest randomized follow-up of the two treatments reported so far. Following, there is an expert commentary by Dr. James Spies, Chair of Radiology at Georgetown University. The Premise: Since 1995, UAE has been described as an alternative to hysterectomy for symptomatic fibroids. EMMY asked whether the benefit holds up a decade later.The Trial: 28 Dutch hospitals randomized 177 premenopausal women with heavy menstrual bleeding from fibroids, all eligible for hysterectomy, 1:1 between 2002 and 2004. 81 underwent UAE and 75 hysterectomy, with a mean follow-up of 133 months.Efficacy: By 10 years, 28 of 81 UAE patients (35%) had a secondary hysterectomy, 5 of them between years 5 and 10. About two-thirds avoided hysterectomy, and the success rate was 69% after an initially successful UAE.Quality of Life: Generic quality of life improved after treatment in both groups and stayed stable at 10 years with no difference between arms. Urinary and bowel function scores fell in both groups, probably from aging, without significant differences between arms.Satisfaction: 78% of UAE patients and 87% of hysterectomy patients were (very) satisfied (P = .77), and 81% versus 84% would recommend their treatment to a friend.The Catch: Secondary hysterectomies kept accruing beyond 5 years, and UAE failure was associated with BMI above 25 (OR 3.29) and smoking (OR 3.24), so long-term follow-up matters when counseling patients.Expert Take: Dr. Spies calls EMMY one of the landmark studies in uterine embolization, but notes issues that may skew long-term results: 17% of patients did not have both uterine arteries embolized and were counted as procedural failures, partly because many sites were performing their first embolizations, and patient management was handled entirely by gynecologists. As the longest follow-up of a randomized trial, and unlikely to be matched in quality, he says it remains the gold standard for long-term outcomes.Tune in to learn why UAE is a well-documented, less invasive alternative to hysterectomy that eligible patients should be counseled on. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. de Bruijn AM, Ankum WM, Reekers JA, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. Am J Obstet Gynecol. 2016. https://doi.org/10.1016/j.ajog.2016.06.051
Oct 7

Beyond the Drug: What Makes TACE Work?

This episode breaks down PRECISION V, the 2010 randomized trial that helped make drug-eluting beads a standard option for hepatocellular carcinoma (HCC), and tests its conclusions against later bland-bead and anatomy data. Following, there is an expert commentary by Dr. Premal Trivedi, Chief of Interventional Radiology at the University of Colorado. The Premise: Conventional TACE uses an unstable lipiodol emulsion that leaks doxorubicin into the systemic circulation. Drug-eluting beads promised to hold the drug in the tumor and block flow permanently.Efficacy: In about 200 BCLC A/B patients, six-month objective response was 51.6% with DC Bead versus 43.5% with conventional TACE (p = 0.11), so the trial missed its primary endpoint. A post hoc advanced-disease subgroup favored the beads (52.4% versus 34.7%).Toxicity: Bead patients received more doxorubicin but had far less alopecia (1.1% versus 20.4%), lower peak ALT and preserved LVEF. Post-embolization syndrome was nearly identical.The Catch: The MSKCC Brown trial compared doxorubicin-loaded beads with bland beads and found essentially the same response and survival, which suggests ischemia, not the drug, is doing the work.Caveats: The trial was an industry-sponsored phase II study with six months of follow-up and no survival endpoints. It was underpowered once the control arm outperformed expectations.Expert Take: Dr. Trivedi notes that systemic doxorubicin alone yields only about a 10% response in HCC, and that most of TACE's benefit comes from the depth and completeness of ischemia.Tune in to learn why the embolization, not the chemotherapy, may be doing the heavy lifting in TACE. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52.
Sep 30

Infra-popliteal Bioresorbable Stents: The NEJM LIFE-BTK Trial

This episode breaks down LIFE-BTK, the 2024 New England Journal of Medicine randomized trial testing whether a drug-eluting resorbable scaffold beats plain balloon angioplasty for infrapopliteal artery disease in chronic limb-threatening ischemia. The Premise: Below the knee has been a graveyard of failed devices. A scaffold that resists recoil, elutes an antiproliferative drug, then dissolves promises structural support without a permanent metal cage.Efficacy: In 261 CLTI patients randomized 2:1, one-year freedom from the primary composite was 74% with the scaffold versus 44% with angioplasty, though the separation was driven largely by binary restenosis (76% versus 50%).Acute Mechanics: Core-lab technical success was 91% versus 70%, with bailout stenting needed in 6% of angioplasty cases and none in the scaffold arm.The Catch: Every major safety event was in the scaffold arm, including two perioperative deaths and four above-ankle amputations, three in limbs with patent scaffolds. Wound healing was numerically lower (45% versus 56%).Durability: As the scaffold resorbs, the benefit holds. At three years the composite endpoint remained higher for the scaffold, 59.5% versus 44.8%.Caveats: Only about 3% of screened patients enrolled, lesions were short and lightly calcified, vessel prep was mandatory only in the scaffold arm, and DAPT ran 12 months versus 1, all favoring the scaffold.Tune in to learn how the first fully resorbable below-the-knee scaffold stacked up against angioplasty, and where the trial's design should temper how you apply it. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Varcoe RL, DeRubertis BG, Kolluri R, et al. Drug-eluting resorbable scaffold versus angioplasty for infrapopliteal artery disease. N Engl J Med. 2024;390:9-19. https://doi.org/10.1056/NEJMoa2305637
Sep 23

Fractured IVC Filter Fragments: The Penn Perspective

This episode features expert commentary from Dr. Scott Trerotola of Penn Medicine, responding to our recent episode on Stanford's fractured IVC filter registry titled, Fractured IVC Filter Fragments: When to Chase the Metal. Shared Ceiling: Both the Penn and Stanford series found that, at best, about half of patients leave with every fragment removed. Some extravascular fragments can still be reached by direct CT- or fluoro-guided puncture.Pulmonary Is Not a Parking Spot: Dr. Trerotola argues that a fragment moving from the heart into the lungs is not a success. Fragments can be coughed up or reach the systemic circulation, and removal is low risk in experienced hands.Radiation in Perspective: Penn's median fluoroscopy time was 27 minutes, so dose should not drive the decision.Tune in to hear why a fragment in the lung is still worth chasing.
Sep 16

The Golden Era of PE Trials: PRAGUE-26

This episode breaks down PRAGUE-26, a 558-patient NEJM randomized trial from 11 Czech centers testing whether low-dose thrombolysis through cheap generic infusion catheters beats anticoagulation alone, with expert commentary throughout from Dr. Jay Giri of Penn Medicine. The Protocol: Standard 4 French infusion catheters, no ultrasound facilitation, alteplase capped at 20 mg over a mean infusion of 9.3 hours. Median time from randomization to lysis was 76 minutes.The Result: The 7-day composite of death, recurrent PE, or cardiorespiratory decompensation fell from 6.8% to 0.7%, with faster RV recovery and shorter ICU stays.What Drove It: Decompensation, not mortality. The endpoint included a NEWS score of 9 or higher, more sensitive than the vasopressor or arrest criteria used in PEITHO.The Bleeding Tradeoff: Major bleeding was neutral, but two intracranial hemorrhages occurred in the thrombolysis arm versus zero with anticoagulation.The Cost Argument, Examined: Generic catheters are cheaper to buy, but Dr. Giri notes that US reimbursement places EKOS cases in a different DRG that covers the catheter. This was also not a head-to-head test of ultrasound facilitation.Caveats: Open-label with an unblinded events committee, no screening logs, a single homogeneous population, and no one over 80.Tune in to learn where this trial actually moves the needle, and where the enthusiasm outruns the data. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Kroupa J, Radvan M, Mrozek J, et al. Catheter-directed thrombolysis in intermediate-high-risk pulmonary embolism. N Engl J Med. Published online August 31, 2026. doi:10.1056/NEJMoa2608012

5

out of 5

2 Ratings

We deliver short, focused episodes on the main concepts and procedures you actually need to know. It’s the perfect clinical companion for your drive to work or your daily workout. Come learn IR on the go! Check us out at https://www.medicalwysdom.ai/

Creator

Wysdom
Years Active

2025 - 2026
Episodes

56
Rating

Clean
Copyright

© 2026 Wysdom
Show Website

Wysdom Radio™

Medicine

Medicine

Updated Weekly
Medicine

Medicine

Updated Weekly